Evaluation of the Hypoallergenicity of a New Formula Based on Hydrolyzed Rice Proteins
1 other identifier
interventional
72
3 countries
4
Brief Summary
The aim of this study is to show the hypoallergenicity of a new thickened rice based formula (TRHF) through a double blind placebo controlled food challenge (DBPCFC), as recommended by the American Academy of Pediatrics, in subjects with IgE-mediated CMA and in subjects with non-IgE-mediated CMA.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Aug 2018
Typical duration for not_applicable
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 14, 2018
CompletedFirst Posted
Study publicly available on registry
June 15, 2018
CompletedStudy Start
First participant enrolled
August 23, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 21, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
September 21, 2020
CompletedNovember 4, 2020
November 1, 2020
2.1 years
May 14, 2018
November 3, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
hypoallergenicity
the percentage of children tolerating the formula during the double blind placebo controlled food challenge (TRHF 2017 vs. placebo formula).
7 days
Secondary Outcomes (18)
Regurgitations
1, 2, 3, 4, 5 and 6 months
Vomiting
1, 2, 3, 4, 5 and 6 months
Abdominal pain
1, 2, 3, 4, 5 and 6 months
Bloating and gas
1, 2, 3, 4, 5 and 6 months
Stool consistency
1, 2, 3, 4, 5 and 6 months
- +13 more secondary outcomes
Study Arms (2)
TRHF - Placebo
EXPERIMENTALEach subjects will receive both TRHF and placebo formula during the 1st part of the study
Placebo - TRHF
PLACEBO COMPARATOREach subjects will receive both TRHF and placebo formula during the 1st part of the study
Interventions
formula previously tolerated by the subject - only for the 1st part of the study
Eligibility Criteria
You may qualify if:
- free of clinical allergic symptoms for at least one week (i.e. successfully fed an elimination diet);
- whose parents signed the informed consent
You may not qualify if:
- mainly breast fed, drinking less than 250ml of formula/day, presenting any situation, which, according to the investigator, may interfere with the study participation or lead to a particular risk for the subject
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- United Pharmaceuticalslead
- Statiteccollaborator
Study Sites (4)
CHR Namur
Namur, Belgium
Hôpital Saint Vincent de Paul - GHICL
Lille, 59000, France
Hopital Trousseau
Paris, France
University of Naples Federico II
Naples, Italy
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Roberto Berni Canani
University Federico II
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 14, 2018
First Posted
June 15, 2018
Study Start
August 23, 2018
Primary Completion
September 21, 2020
Study Completion
September 21, 2020
Last Updated
November 4, 2020
Record last verified: 2020-11